United Therapeutics Corporation (UTHR)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $25.18B
Last updated: Nov 17, 2026 at 11:06 AM ET
United Therapeutics Corporation (UTHR) Stock Forecast
Analysts expect United Therapeutics (UTHR) to earn $24.96 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.26B. Of 15 analysts, 11 rate the stock Buy or Strong Buy, 3 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 7 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 2.13, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 73% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 20.0% |
| Buy | 8 | 53.3% |
| Hold | 3 | 20.0% |
| Sell | 1 | 6.7% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 26.0% and revenue estimates rise 10.4%.
- Fiscal year ending Dec 31, 2026
- $24.96
- EPS consensus, revenue $3.26B
- Fiscal year ending Dec 31, 2027
- $31.44
- EPS consensus, revenue $3.60B
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $24.96 | $22.05 to $28.86 | 13 | $3.26B | $3.09B to $3.55B | 13 |
| Dec 31, 2027 | $31.44 | $20.71 to $39.88 | 14 | $3.60B | $2.80B to $4.06B | 14 |
Quarterly Estimates
The EPS consensus falls from $6.89 for the quarter ending Dec 31, 2026 to $6.53 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $6.89 | $2.99 to $13.46 | 16 | $879.42M | $679.32M to $1.21B | 15 |
| Mar 31, 2027 | $6.53 | $5.21 to $7.41 | 5 | $790.07M | $688.00M to $849.73M | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 19 upward and 2 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 7 | 2 |
| Fiscal year ending Dec 31, 2027 | 11 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 5.0% from $26.27.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $24.96 | $26.63 | $26.16 | $26.04 | $26.27 | -5.0% |
| Fiscal year ending Dec 31, 2027 | $31.44 | $31.14 | $30.20 | $28.69 | $28.94 | +8.7% |
| Quarter ending Mar 31, 2027 | $6.53 | $7.29 | $6.48 | $6.33 | $6.41 | +1.9% |
Frequently Asked Questions About UTHR
What is the UTHR stock forecast?
Consensus analyst estimates put United Therapeutics's EPS at $24.96 for the fiscal year ending Dec 31, 2026, on revenue of $3.26B. The consensus rating from 15 analysts is Buy.
How do analysts rate UTHR stock?
Of 15 analysts covering United Therapeutics, 3 rate it Strong Buy, 8 Buy, 3 Hold, 1 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from UTHR next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $24.96, with estimates from $22.05 to $28.86 from 13 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $31.44, with estimates from $20.71 to $39.88 from 14 analysts.
What revenue do analysts expect from United Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.26B, with estimates from $3.09B to $3.55B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $3.60B, with estimates from $2.80B to $4.06B.
How many analysts cover UTHR?
15 analysts rate United Therapeutics stock, and 13 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
UTHR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts